Plasmapheresis. Technical aspects and indications (Q33342767)

26 July 2017

1 reference

title

Plasmapheresis. Technical aspects and indications (English)

1 reference

26 July 2017

François Madore

1

1 reference

26 July 2017

publication date

1 April 2002

1 reference

26 July 2017

published in

Critical Care Clinics

1 reference

26 July 2017

volume

18

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

375-392

1 reference

Plasma exchange in acute renal allograft rejection. A controlled trial

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

THROMBOTIC THROMBOCYTOPENIC PURPURA

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Plasmapheresis and pulse cyclophosphamide in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Treatment of Thrombotic Thrombocytopenic Purpura with Plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Regulation of antibody formation by serum antibody. II. Removal of specific antibody by means of exchange transfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

A comparison of centrifugal and membrane-based apheresis formats.

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Therapeutic apheresis for renal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Extracorporeal adsorbent-based strategies in sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Treatment of Renal Failure Associated With Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

A controlled trial of plasmapheresis in the treatment of renal allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Reversal of Impaired Splenic Function in Patients with Nephritis or Vasculitis (or Both) by Plasma Exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

The nonspecific clearance function of the reticuloendothelial system in patients with immune complex mediated diseases before and after therapeutic plasmapheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Management of myeloma kidney: an anti-light-chain approach

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Therapeutic plasma exchange: complications and management

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Plasma exchange in progressive IgA nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Treatment of rapidly progressive IgA nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Therapeutic Plasma Exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Plasma exchange in Goodpasture's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Plasmapheresis in severe sepsis or septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Improved survival in multiple myeloma with renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Randomised trial of plasma exchange in mild systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Anti-glomerular basement membrane antibody-induced glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

Therapeutic apheresis in renal and metabolic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0749-0704%2801%2900010-0

7 January 2021

10.1016/S0749-0704(01)00010-0

Identifiers

DOI

1 reference

26 July 2017

1 reference